Cardiac Toxicity of Targeted Therapies Used in the Treatment for Solid Tumours: A Review

BRIM-2: An open-label, multicenter phase II study of vemurafenib in previously treated patients with BRAF V600E mutation-positive metastatic melanoma.

(2017) A. Ribas et al.   JOURNAL OF CLINICAL ONCOLOGY

AMP-activated protein kinase: a cellular energy sensor with a key role in metabolic disorders and in cancer

(2011) D. Grahame Hardie   BIOCHEMICAL SOCIETY TRANSACTIONS

Cancer Immunotherapy

(2011) Robert O. Dillman   CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS

Dasatinib: An Anti-Tumour Agent via Src Inhibition

(2011) Antonio Gnoni et al.   CURRENT DRUG TARGETS

Sunitinib, Hypertension, and Heart Failure: A Model for Kinase Inhibitor-Mediated Cardiotoxicity

(2011) Rajesh Gupta et al.   CURRENT HYPERTENSION REPORTS

Efficacy and Safety of Sirolimus and Everolimus in Heart Transplant Patients: A Retrospective Analysis

(2011) B. Baur et al.   TRANSPLANTATION PROCEEDINGS

Cardiotoxicity

(2010) I. Brana et al.   ANNALS OF ONCOLOGY

Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study

(2010) S. J. O'Day et al.   ANNALS OF ONCOLOGY

Molecular Mechanisms of Cardiovascular Toxicity of Targeted Cancer Therapeutics

(2010) Hui Cheng et al.   CIRCULATION RESEARCH

The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II/III trial

(2010) Markus M. Heiss et al.   INTERNATIONAL JOURNAL OF CANCER

Cardiomyocyte PDGFR-β signaling is an essential component of the mouse cardiac response to load-induced stress

(2010) Vishnu Chintalgattu et al.   JOURNAL OF CLINICAL INVESTIGATION

Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial

(2010) Cora N. Sternberg et al.   JOURNAL OF CLINICAL ONCOLOGY

Role of Biomarkers in Chemotherapy-Induced Cardiotoxicity

(2010) Daniela Cardinale et al.   PROGRESS IN CARDIOVASCULAR DISEASES

The lack of target specificity of small molecule anticancer kinase inhibitors is correlated with their ability to damage myocytes in vitro

(2010) Brian B. Hasinoff et al.   TOXICOLOGY AND APPLIED PHARMACOLOGY

Cardiotoxicity induced by tyrosine kinase inhibitors

(2009) George S. Orphanos et al.   ACTA ONCOLOGICA

Bevacizumab-associated hypertension: etiology, incidence, and management

(2009) Sergio Huerta et al.   ANTI-CANCER DRUGS

Anticancer drugs and cardiotoxicity: Insights and perspectives in the era of targeted therapy

(2009) Emanuel Raschi et al.   PHARMACOLOGY & THERAPEUTICS

Cardiotoxicity associated with the cancer therapeutic agent sunitinib malate

(2008) M. L. Telli et al.   ANNALS OF ONCOLOGY

Arterial hypertension correlates with clinical outcome in colorectal cancer patients treated with first-line bevacizumab

(2008) M. Scartozzi et al.   ANNALS OF ONCOLOGY

Mechanisms of Cardiac Dysfunction Associated With Tyrosine Kinase Inhibitor Cancer Therapeutics

(2008) Ming Hui Chen et al.   CIRCULATION

Cardiac Toxicity in Breast Cancer Survivors: Review of Potential Cardiac Problems

(2008) B. R.J. H. Bird et al.   CLINICAL CANCER RESEARCH

Cardiac Toxicity of Sunitinib and Sorafenib in Patients With Metastatic Renal Cell Carcinoma

(2008) Manuela Schmidinger et al.   JOURNAL OF CLINICAL ONCOLOGY

Incidence and risk of hypertension with sorafenib in patients with cancer: a systematic review and meta-analysis

(2008) Shenhong Wu et al.   LANCET ONCOLOGY

Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling

(2008) Scott M. Wilhelm et al.   MOLECULAR CANCER THERAPEUTICS

Tackling heart failure in the twenty-first century

(2008) James O. Mudd et al.   NATURE

Targeted Therapies for Metastatic Renal Cell Carcinoma: An Overview of Toxicity and Dosing Strategies

(2008) T. E. Hutson et al.   ONCOLOGIST